Pharmaceutical

Lilly counting on diabetes products to challenge larger rivals

October 8, 2012
Bloomberg News
Eli Lilly and Co. is betting on a “broad” range of diabetes products including pills, insulins and a once-a-week treatment to take on bigger competitors, said Enrique Conterno, president of Lilly Diabetes.
More

Group aims to cut costs of late-stage drugs

September 24, 2012
J.K. Wall
You know things are bad in the fiercely competitive pharma industry when drugmakers start turning to each other for help. But that’s exactly what happened last week when 10 major drug companies—including Eli Lilly and Co.—joined forces to cut costs out of clinical trials.
More

Lilly's Cialis gets European endorsement for new use

September 21, 2012
Associated Press
A European committee has endorsed the use of Eli Lilly and Co.'s erectile dysfunction drug Cialis to treat symptoms tied to an enlarged prostate.
More

Ten drugmakers team up to improve testing process

September 19, 2012
Associated Press
Pharmaceutical industry heavyweights, including Eli Lilly and Co., are teaming up to improve the way experimental drugs are tested so they can get approved, and reach patients, faster.
More

Two more clinical trials go against Lilly

September 4, 2012
J.K. Wall
In the midst of Eli Lilly and Co.’s surprisingly positive news about its experimental Alzheimer’s drug, the company suffered two other setbacks with former stars of its pipeline.
More

Lilly stops testing of experimental schizophrenia drug

August 29, 2012
Bloomberg News
Eli Lilly and Co. halted testing on an experimental treatment for schizophrenia after the company determined the drug was unlikely to show a benefit in patients.
More

Lilly's Alzheimer's finding triggers investor hope, doctor caution

August 27, 2012
Bloomberg News
While investors supported the sliver of promise offered when Eli Lilly and Co. said its Alzheimer’s drug may slow progression early in the disease, doctors weren’t as impressed, saying it could take years to find out for sure.
More

Lilly wins appeal upholding patent for Alimta cancer drug

August 24, 2012
Bloomberg News
Eli Lilly and Co. won a U.S. appeals court ruling that upholds the validity of a patent for the lung-cancer drug Alimta and blocks generic competition through 2017. Alimta generated $2.5 billion in sales last year.
More

Lilly's Alzheimer's drug trials show mixed results

August 24, 2012
Bloomberg News, J.K. Wall
Eli Lilly and Co.’s experimental Alzheimer’s drug failed to meet its primary goals in two separate clinical trials. However, when the results of both trials were combined, the drug appeared to have slowed the decline of cognition in some patients.
More

Lilly stock slips after competitors halt Alzheimer's plans

August 7, 2012
 IBJ Staff and Bloomberg News
Pfizer Inc., Johnson & Johnson and Elan Corp. are ending most plans to develop an Alzheimer’s drug after a second trial failure. Eli Lilly is developing a similar treatment.
More

Despite funding dip, IU bets on brains

August 6, 2012
J.K. Wall
The city that brought the world Prozac and other neuroscience drugs is doubling down on brain research with a new $52 million research center near Methodist Hospital.
More

McKesson to pay $151M to settle drug-pricing suit

July 27, 2012
Associated Press
Twenty-nine states, including Indiana, have reached a $151 million settlement in a lawsuit alleging one of the country's largest drug wholesalers inflated prices for hundreds of prescription drugs, officials said Friday.
More

Lilly's quarterly profit falls, but tops analyst expectations

July 25, 2012
Bloomberg News
Eli Lilly and Co. reported second-quarter profit that fell less than analysts had expected. The company raised its outlook for the rest of the year.
More

Potential Alzheimer’s drug fails first of four key trials

July 24, 2012
Bloomberg News
Bapineuzumab is in a race with a similar product from Indianapolis-based Eli Lilly and Co. to become the first therapy to target a cause for Alzheimer’s, rather than just its symptoms.
More

Potential Lilly antipsychotic falls short in study

July 11, 2012
Associated Press
Eli Lilly and Co. said a potential treatment for acute schizophrenia failed in a late-stage study that compared patients taking the drug to those taking a placebo.
More

Lilly gets 6-month Cymbalta marketing extension

July 6, 2012
Associated Press
Eli Lilly and Co. said Friday that it has received an extra six months of marketing exclusivity on the antidepressant Cymbalta, its biggest selling drug. The extension could mean more than a billion dollars in sales for the Indianapolis drug maker.
More

Lilly cancer treatment fails trial in stomach cancer

July 5, 2012
 IBJ Staff and Bloomberg News
Erbitux, a cancer treatment made by Indianapolis-based Eli Lilly and Co.'s Imclone unit, failed to help patients with advanced stomach tumors in a late-stage clinical trial.
More

Bristol-Myers to buy former Lilly partner Amylin for $5.3B

June 30, 2012
Bloomberg News
Bristol-Myers Squibb Co. has agreed to pay $5.3 billion to acquire former Eli Lilly and Co. partner Amylin Pharmaceuticals Inc., a maker of diabetes therapies. The deal is valued at about $7 billion, which includes Amylin’s debt and a payment to Eli Lilly and Co. of about $1.7 billion.
More

Lilly resumes $3B stock buyback program, declares dividend

June 19, 2012
Associated Press
The local pharmaceutical giant plans to complete the program started in 2000 by repurchasing $420 million in shares by the end of the year. And on Tuesday, it declared a regular dividend of 49 cents.
More

Lilly sinks $20M into Chinese firm for 'branded generic' drugs

June 12, 2012
J.K. Wall
Eli Lilly and Co. has invested $20 million in Chinese pharmaceutical company Novast Labs in an effort to build up a portfolio of branded generic medicines in the fast-growing Asian market.
More

Lilly chases Novo in insulin race

June 11, 2012
J.K. Wall
Eli Lilly and Co. announced positive results for an experiemental insulin at the annual American Diabetes Association conference in Philadelphia, but was still upstaged by Denmark-based Novo Nordisk A/S.
More

FDA’s $6.4B drug review fee plan passes Senate

May 24, 2012
Bloomberg News
The U.S. Senate voted to let regulators collect on a $6.4 billion fee agreement struck with Indianapolis-based Eli Lilly and Co., Medtronic Inc. and other companies to fund reviews of new drugs and medical devices through 2017.
More

Good cholesterol may not lower heart risk, study suggests

May 17, 2012
Bloomberg News
Raising good cholesterol, a goal pursued by Eli Lilly and Co. as the next milestone in cardiac care, may not cut heart-attack risk, says a study that challenges the development of drugs that may someday generate billions of dollars in sales.
More

U.S. losing drug-research jobs to other countries

May 17, 2012
Bloomberg News
Eli Lilly and other big pharmaceutical companies are creating thousands of research jobs overseas as countries led by Singapore, Ireland and South Africa boost incentives.
More

Lilly unlikely to gain from Plavix patent loss, analyst says

May 17, 2012
Bloomberg News
Indianapolis-based Eli Lilly and Co. and London-based AstraZeneca Plc aren't expected to have an easier time gaining more of the market for blood thinners dominated by Bristol-Myers Squibb Co.’s Plavix after the drug loses U.S. patent protection Thursday.
More
Page  << 1 2 3 4 5 6 7 8 9 10 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Why should citizens rates increase forever to basically reduce Dukes cost to operate in the future? They will have no meter readers, no connect/disconnect personnel and will need fewer lineman to handle the same number of customers. Add to that the ability to replace customer service by giving detailed information electronically. Why do we have to subsidize the cost cutting measures of a Public Utility?

  2. In response to Sassafras, I have to ask if you relocated directly from Bloomington to Carmel? First, as you point out, Carmel is 48 square miles. Do you think it’s possible that some areas are more densely developed than others? That might explain traffic density in some places while others are pretty free moving. Second, your comment “have you ever been to Chicago--or just about any city outside of Indiana?” belies your bias. I don’t know, Sassafras, have you never been to Nashville, Columbus, OH, Cincinnati, St. Louis, Kansas City, Denver, Phoenix? They’re not a lot different in density than Indy. One more thing…I understand these comment sections are for expressing opinions, so those of us just looking for facts have to be patient, but you mention “low-density” Indy. How many cities in the US comprise 400 square miles with about 10% of that still being agricultural? Those facts certainly can impact the statistics.

  3. With all the past shady actions of Duke with utility regulators, one wonders do they really need such a huge amount? Concerned regulators not protecting ratepayers from the aggressive Duke monolith.

  4. I thought that had to be the way it was but had to ask because I wasn't sure. Thanks Again!

  5. I could be wrong, but I don't think Butler views the new dorm as mere replacements for Schwitzer and or Ross.

ADVERTISEMENT